In a prospective cohort, a 3-gene blood model predicted 1-year castration resistance with an AUC of 0.89 in metastatic ...

A large integrated transcriptomic study shows that rising cancer stemness tracks prostate cancer progression, lineage ...

Subcapsular vs total orchiectomy had higher satisfaction, with the tradeoff of less testosterone and PSA suppression. Patients with advanced prostate cancer undergoing surgical castration are more ...

Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy is safe and effective for patients with ...

Darolutamide (Nubeqa) is granted FDA approval for metastatic castration-sensitive prostate cancer, enhancing survival and quality of life for patients. The FDA has approved darolutamide (Nubeqa; Bayer ...

Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the ...